GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » EBITDA Margin %

Waverley Pharma (TSXV:WAVE) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Waverley Pharma's EBITDA for the three months ended in Mar. 2024 was C$-0.23 Mil. Waverley Pharma's Revenue for the three months ended in Mar. 2024 was C$0.00 Mil. Therefore, Waverley Pharma's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Waverley Pharma EBITDA Margin % Historical Data

The historical data trend for Waverley Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma EBITDA Margin % Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -122.21 -50.98 -43.30 -42.50 -221.36

Waverley Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -207.56 -97.32 -217.71 -632.65 -

Competitive Comparison of Waverley Pharma's EBITDA Margin %

For the Biotechnology subindustry, Waverley Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waverley Pharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's EBITDA Margin % falls into.



Waverley Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Waverley Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-0.912/0.412
=-221.36 %

Waverley Pharma's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.232/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waverley Pharma  (TSXV:WAVE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Waverley Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma (TSXV:WAVE) Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Executives
Albert David Friesen 10% Security Holder, Director, Senior Officer

Waverley Pharma (TSXV:WAVE) Headlines

From GuruFocus

California Senate Approves Wave and Tidal Renewable Energy Bill

By PRNewswire PRNewswire 06-20-2023